Too soon for Novartis's serelaxin, says CHMP
This article was originally published in Scrip
Executive Summary
The EU's CHMP has knocked back Novartis's application for conditional approval of its acute heart failure treatment serelaxin (RLX030), ahead of its US FDA panel meeting in a few weeks.